<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746486</url>
  </required_header>
  <id_info>
    <org_study_id>BUC-56/PBC</org_study_id>
    <secondary_id>2007-004040-70</secondary_id>
    <nct_id>NCT00746486</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study Comparing the Combination of Ursodeoxycholic Acid Capsules Plus Budesonide Capsules to Ursodeoxycholic Acid Capsules Plus Placebo in the Treatment of Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to compare the efficacy and tolerability of a combination therapy with
      ursodeoxycholic acid (12-16 mg/kg body weight (BW)/d) plus budesonide (9 mg/d) vs.
      ursodeoxycholic acid (12-16 mg/kg BW/d) plus placebo in the treatment of PBC. Depending on
      ALT values 6 mg/d budesonide are allowed. The study population will be patients with PBC at
      risk for disease progression. It is assumed that the combination therapy will result in a
      decrease of treatment failures after 3 years of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped based on the recommendation of the IDMC after a planned Interim Analysis
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients without treatment failure after 3 years of treatment</measure>
    <time_frame>3 years, LOCF</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>course of pruritus</measure>
    <time_frame>3 years, LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>course of fatigue</measure>
    <time_frame>3 years, LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>course of Mayo Risk score</measure>
    <time_frame>3 years, LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>3 years, LOCF</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide placebo</intervention_name>
    <description>One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Age ≥ 18 years

          3. UDCA treatment for at least 6 months prior to inclusion

          4. Liver biopsy compatible with PBC

          5. Liver biopsy performed within the last 6 months prior to inclusion

          6. PBC patients at risk of disease progression based on one or more of the following
             criteria:

               -  Serum alkaline phosphatase ≥ 3 times the upper limit of normal at any time since
                  diagnosis of PBC and ALT ≥ 2 times upper limit of normal or

               -  Total Bilirubin ≥ 1.0 mg/dl (≥ 17 µmol/L) or

               -  Moderate to severe periportal or periseptal lymphocytic interface hepatitis or

               -  Periportal and portal fibrosis with numerous septa (Ludwig stage III) without
                  cirrhosis

          7. Type 2 anti-mitochondrial antibodies &gt; 1:40 by direct immunofluorescence

          8. Women of child-bearing potential have to apply appropriate contraceptive methods,
             e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of
             contraception (e.g., use of a condom and spermicide), partner has undergone vasectomy
             and subject is in monogamous relationship. The investigator is responsible for
             determining whether the subject has adequate birth control for study participation

        Exclusion Criteria:

          1. Histologically proven cirrhosis

          2. Positive Hepatitis B or C serology

          3. Positive HIV serology

          4. Primary Sclerosing Cholangitis

          5. Wilson's-Disease

          6. Celiac Disease (blood tests and/or oesophago-gastro-duodenoscopy with histological
             examination to be performed)

          7. α1-anti-Trypsin-deficiency

          8. Haemochromatosis

          9. Autoimmune-Hepatitis (AIH; defined by an Alvarez score &gt; 15 without treatment or ≥ 17
             with treatment); Note: PBC/AIH overlap disease, treated insufficiently with UDCA
             monotherapy may be enrolled

         10. Treatment with any of the following drugs within the last 3 months prior to inclusion:
             colchicine, corticosteroids, azathioprine or other immunosuppressive drugs (e.g.
             cyclosporine, methotrexate), chlorambucil, D-penicillamine, fibrates, or
             antihyperlipidemic drugs

         11. Treatment with ketoconazole or other CYP3A inhibitors within the last 4 weeks before
             baseline; rifampicin (up to 600 mg/d) is allowed to treat pruritus until baseline

         12. Sonographic or endoscopic signs of portal hypertension

         13. Ascites or history of ascites

         14. Hepatic encephalopathy or history of hepatic encephalopathy

         15. Total bilirubin &gt; 3.0 mg/dl (&gt; 50 µmol/L)

         16. Albumin &lt; 36 g/L

         17. Prothrombin ratio &lt; 70%

         18. Platelet count &lt; 135.000/mm3

         19. Osteoporosis proven by bone densitometry

         20. Diabetes mellitus, defined as B-Glucose &gt; 125 mg/dl on an empty stomach (even when
             controlled)

         21. Hypertension, defined as persistent raised blood pressure &gt; 140/90 mmHg

         22. Suspected non-compliance of the patient (suspected difficulties to comply with the
             study period of 36 months)

         23. Severe co-morbidity substantially reducing life expectancy

         24. Known intolerance/hypersensitivity/resistance to study drugs or drugs of similar
             chemical structure or pharmacological profile

         25. Existing or intended pregnancy or breast-feeding

         26. Participation in another clinical trial within the last 30 days, simultaneous
             participation in another clinical trial, or previous participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raoul Poupon, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine, 75571 Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

